Evidence map›Paper›PMID 30972577›Full record

ArticleClinical rheumatology2019

Correction to: Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.

Rieke Alten, Xavier Mariette, Hanns-Martin Lorenz, Hubert Nüßlein, Mauro Galeazzi, Federico Navarro, Melanie Chartier, Julia Heitzmann, Coralie Poncet, Christiane Rauch and 1 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Rieke AltenDepartment of Internal Medicine, Rheumatology, Clinical Immunology, and Osteology, Schlosspark-Klinik University Medicine Berlin, Heubnerweg 2, 14059, Berlin, Germany. rieke.alten@schlosspark-klinik.de.
Xavier MarietteDepartment of Rheumatology, Université Paris-Sud, Paris, France.
Hanns-Martin LorenzDepartment of Rheumatology, University Hospital, Heidelberg, Germany.
Hubert NüßleinDepartment of Internal Medicine and Rheumatology, University of Erlangen-Nuremberg, Nuremberg, Germany.
Mauro GaleazziDepartment of Medical Sciences, Surgery, and Neuroscience, University of Siena, Siena, Italy.
Federico NavarroDepartment of Rheumatology, Hospital Universitario Virgen Macarena, Seville, Spain.
Melanie ChartierMarketed Product Late Stage Operation Department, Bristol-Myers Squibb, Rueil-Malmaison, France.
Julia HeitzmannExcelya, Boulogne-Billancourt, France.
Coralie PoncetDocs International, Issy-les-Moulineaux, France.
Christiane RauchDepartment of Immunoscience, Bristol-Myers Squibb, Munich, Germany.
Manuela Le BarsSpeciality Development Immunology, Bristol-Myers Squibb, Rueil-Malmaison, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article listed above was initially published with incorrect copyright information. Upon publication of this Correction, the copyright of this article changed to "The Author(s)". The original article has been corrected.

Identifiers

PMID30972577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.